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A B S T R A C T
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with antiretroviral
drugs alone. Latency reversing agents (LRAs) can activate HIV expression in latently infected cells, potentially
leading to their elimination through virus-mediated cytopathic effects, host immune responses, and/or ther-
apeutic strategies targeting cells actively expressing virus. We have recently described several structurally
simplified analogs of the PKC modulator LRA bryostatin (termed bryologs) designed to improve synthetic ac-
cessibility, tolerability in vivo, and efficacy in inducing HIV latency reversal. Here we report the comparative
performance of lead bryologs, including their effects in reducing cell surface expression of HIV entry receptors,
inducing proinflammatory cytokines, inhibiting short-term HIV replication, and synergizing with histone dea-
cetylase inhibitors to reverse HIV latency. These data provide unique insights into structure-function relation-
ships between A- and B-ring bryolog modifications and activities in primary cells, and suggest that bryologs
represent promising leads for preclinical advancement.
1. Introduction
Infection with human immunodeficiency virus (HIV) almost in-
variably causes severe damage to the host immune system, leading to
the development of acquired immunodeficiency syndrome (AIDS). This
process can be inhibited by the administration of antiretroviral therapy
(ART), which blocks HIV replication and often reduces HIV RNA viral
loads to levels below the limit of detection using standard clinical as-
says (approximately 50 copies per mL of plasma) (Dinoso et al., 2009;
Gulick et al., 1997; Perelson et al., 1997). However, if ART is stopped,
viral replication rapidly resumes allowing disease progression to con-
tinue (Chun et al., 1999a). As a result, ART requires strict and life-long
compliance to maintain suppression. While multiple factors might
contribute to the persistence of HIV during ART, one important source
of replication-competent HIV in treated patients is latently-infected
CD4+T cells (Chun et al., 1995; Finzi et al., 1999; Finzi et al., 1997;
Wong et al., 1997). These long-lived latently-infected cells harbor in-
tegrated proviruses that express little or no viral RNA and no viral
proteins, but episodically produce infectious virions upon appropriate
stimulation of the host cell (Chun et al., 1997; Finzi et al., 1997).
Elimination of these reservoir cells, the chronic source of re-infection, is
therefore critical for HIV eradication from infected individuals.
One approach for purging latent reservoir cells is to induce ex-
pression of the latent provirus, thereby rendering the host cell suscep-
tible to viral cytopathic effects, immune effector mechanisms, and/or
therapeutic approaches targeted towards viral proteins (Reviewed in
(Marsden and Zack, 2009, 2010; Marsden and Zack, 2015)). Several
clinical efforts to induce HIV expression in latently infected cells have
been undertaken, including administration of interleukin 2 (IL-2) either
alone (Chun et al., 1999b) or in combination with anti-CD3 antibodies
(OKT3) (Kulkosky et al., 2002; Prins et al., 1999; van Praag et al.,
2001). Histone deacetylase inhibitors (HDACi) (Archin et al., 2012;
Lehrman et al., 2005; Rasmussen et al., 2014) and the anti-alcoholic-
abuse agent disulfiram (Elliott et al., 2015) have been tested in a similar
manner. More recent work in this area includes a combined approach
using Vacc-4× , recombinant human granulocyte macrophage colony
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stimulating factor vaccination, and HDACi romidepsin, which was
tested in a phase 1B/2A trial (Leth et al., 2016). The treatments de-
scribed in these important pioneering studies had varying effects on
HIV expression and the relative frequency of latently infected cells,
with several capable of increasing HIV RNA expression or inducing
limited reduction of the latent reservoir in a subset of patients. How-
ever, none of them entirely eliminated replication-competent HIV from
the infected individuals. The more aggressive therapies involving OKT3
and/or IL-2 also resulted in toxic side-effects due to generalized im-
mune activation (Prins et al., 1999; van Praag et al., 2001). This issue of
toxicity associated with HIV LRAs is challenging because expression of
HIV proviral DNA is connected to the activation state of the host cell,
prompting concerns that the most effective HIV latency reversal agents
might also cause global T cell activation, resulting in hypercytokinemia
or a “cytokine storm” that could create unacceptable risks and thus
preclude their clinical use. Therefore, while the “kick and kill” ap-
proach for eliminating latent HIV has been explored in proof-of-concept
clinical studies, more effective and better tolerated agents are required
if latency purging strategies are to be fully effective.
Protein kinase C (PKC) modulators, including prostratin, ingenol,
and bryostatin are of interest in the context of HIV eradication efforts
because they can activate the transcription factor NF-kappa B (Williams
et al., 2004) and induce HIV from latency in various cell and animal
models, as well as primary cells from ART-treated patients (Baxter
et al., 2016; Beans et al., 2013; Bullen et al., 2014; Darcis et al., 2015;
DeChristopher et al., 2012; Jiang et al., 2015; Kinter et al., 1990;
Marsden et al., 2017; Perez et al., 2010; Qatsha et al., 1993). Indeed,
the first phase I clinical trial of bryostatin 1 (hereafter referred to as
bryostatin) has been conducted in ART-treated, HIV-infected in-
dividuals. This study found bryostatin to be safe at the 10 and 20 μg/m2
doses tested, with the results indicating that higher doses would likely
be needed to induce the desired effects on PKC activity in vivo
(Gutierrez et al., 2016). Higher doses (up to approximately 50 μg/m2)
are tolerated, as demonstrated in several oncology trials with bryos-
tatin, but the identification of analogs with an expanded therapeutic
window is a significant objective of ongoing research.
Despite bryostatin's clinical promise, this lead compound is isolated
in very low and variable yields from its marine source (14 t of Bugula
neritina yielded only 18 g of Good Manufacturing Practice-grade [GMP]
bryostatin), raising cost and environmental concerns about its sustain-
able supply from natural sources (Schaufelberger et al., 1991). To ad-
dress this problem, aquaculture was tried but abandoned (Mendola,
2003). Synthetic biological approaches remain in early stages due to
complications arising from cultivation of the symbiotic bacterium that
produces bryostatin (Miller et al., 2016; Trindade-Silva et al., 2010).
The current supply of GMP bryostatin produced in the 1990s is nearly
depleted. Thus while bryostatin continues to serve as a significant
therapeutic lead and an important clinical candidate for multiple in-
dications, the aforementioned therapeutic window and supply issues
have hampered its advancement. Recognizing that bryostatin, like
many natural products, is neither evolved nor optimized for the treat-
ment of human disease, we previously reported the first analogs of
bryostatin that are more synthetically accessible and exhibit activities
comparable or better than bryostatin (Wender et al., 2014, 2015). More
recently we reported a scalable total synthesis of bryostatin that ad-
dresses the clinical supply problem, and importantly is readily adapted
to enable the design and synthesis of superior analog compounds, lead
examples of which are evaluated herein (Wender et al., 2017).
To address these issues of supply and sub-optimal activity, we pre-
viously reported a function-oriented approach to designed syntheti-
cally-accessible bryostatin analogs (DeChristopher et al., 2012; Wender
et al., 1988). We demonstrated that we could effectively recapitulate
the PKC affinities and activities of the natural product with bryostatin
analogs or “bryologs” featuring structural variations in the A- and B-
rings of the macrocyclic scaffold (Fig. 1). This approach also provides
the opportunity to tune the activity of analog compounds to optimize
their performance via targeted structural manipulation of the bryostatin
scaffold. Significantly, these designed bryologs potently induce HIV
expression in a J-Lat model for HIV latency (DeChristopher et al.,
2012). We further established that one particularly efficacious bryolog
(SUW133) could induce HIV from latency ex vivo from CD4+T cells
derived from HIV-infected ART-treated patients and in vivo in huma-
nized BLT mice (Marsden et al., 2017).
In the current study, we address the activities of these bryologs as
required for their preclinical advancement with a focus on their com-
parative ability to alter HIV entry receptor levels and induce proin-
flammatory cytokines in primary peripheral blood mononuclear cells
(PBMC), affect HIV spread in activated CD4+T cells, and synergize
with HDACi to reverse HIV latency. These experiments provide im-
portant insights into how structural variations of bryologs affect HIV
latency reactivation and influence subsequent viral spread.
Significantly, we have found that improved HIV latency reversal ac-
tivity can be achieved with lead bryologs without a corresponding in-
crease in induction of potentially damaging cytokines.
2. Results
2.1. Bryologs reduce cell surface HIV entry receptor levels
Structures for the synthetic bryologs, bryostatin and prostatin used
in this study are provided (Fig. 1). We first explored whether the novel
bryologs share potentially beneficial activities with the parent com-
pound bryostatin, beyond their ability to induce HIV from latency. Not
unlike bryostatin and prostratin (a non-tumor promoting phorbol ester
that similarly activates latent HIV by activating protein kinase C), the
Fig. 1. Structures of compounds. Chemical structures of bryostatin 1, pros-
tratin, and simplified bryostatin analogs (bryologs) are shown. Analogs
SUW128, SUW133, SUW135, SUW127, and SUW134 here correspond to pre-
viously published (DeChristopher et al., 2012) analogs 2, 4, 5, 6, and 7 re-
spectively. SUW132 corresponds to compound 4.55 (Schrier, 2011), and was
prepared in an analogous manner to SUW128 and SUW133 (Wender et al.,
2014).
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bryologs are pan-PKC modulators, binding to all novel and conven-
tional PKC isoforms, although prostratin exhibits 10–100-fold lower
affinities. One property of both bryostatin and prostratin is the capacity
to transiently reduce cell surface levels of the receptors CD4, CCR5, and
CXCR4 (Kulkosky et al., 2001; Mehla et al., 2010; Rullas et al., 2004)
through internalization and degradation in a PKC-dependent pathway
(Hezareh et al., 2004). Cell surface CD4 expression is required for the
entry of nearly all primary HIV isolates (Dalgleish et al., 1984), and
CCR5 (Alkhatib et al., 1996; Deng et al., 1996; Dragic et al., 1996) or
CXCR4 (Feng et al., 1996) are essential coreceptors for infection with
R5-tropic or X4-tropic HIV isolates, respectively. We previously de-
monstrated that a panel of PKC modulators (including several com-
pounds shown in Fig. 1) induced expression of CD69 at the same con-
centrations as that required to induce HIV from latency (Marsden et al.,
2017), however their effects on HIV receptor expression have not been
defined. Therefore, primary CD4+T cells were isolated from healthy
donors and stimulated for 24 h with different concentrations of pros-
tratin, bryostatin, or one of several bryologs. Expression levels of CD4,
CCR5, CXCR4, and CD45 were then quantified by flow cytometry
(Fig. 2). CD45 is expressed on all leukocytes and was included for
control and comparison purposes because its surface expression levels
have not been reported to be affected by PKC modulation. In line with
their relative PKC affinities, prostratin significantly (p < 0.001)
downregulated the expression of CD4 and CXCR4 at a concentration of
1 µM, whereas bryostatin downregulated the expression of these
receptors and also CCR5 at concentrations as low as 1 nM (Figs. 2A and
2B). Similarly, the bryologs tested also downregulated these receptors
at low nanomolar concentrations. The C7-acetoxy or C7-deoxy analogs
(SUW133, SUW135, SUW127, and SUW134) are more potent than the
C7-hydroxyl analogs (SUW128 and SUW132), potentially in agreement
with recent molecular dynamics studies showing that ligands bound to
PKC could influence its positioning in a membrane microenvironment
and thus function (Ryckbosch et al., 2017). CD45 was not significantly
downregulated by any compound tested. Overall, the higher con-
centrations of compound induced greater than 80% reductions in CD4
and CXCR4 mean fluorescent intensity (MFI). The majority of CD4+T
cells obtained directly from healthy human donors are not activated,
and CCR5 expression levels are typically low in these resting cells.
However, each of the tested compounds except for prostratin, SUW128,
and SUW132 induced a significant (p < 0.05) but modest decline in
CCR5 MFI (Fig. 2B).
2.2. Effect of bryologs on short-term HIV spread (replication in culture)
The net effect of treatment with PKC activating agents such as
bryostatin and prostratin on HIV spread is the result of a complex set of
interactions influenced by the positive and negative effects of these
compounds on the different stages of the HIV life cycle. For example,
prostratin and bryostatin can each downregulate HIV entry receptor
levels and inhibit virus entry (Fig. 2), but upregulate HIV expression
Fig. 2. Compound-induced reduction of cell surface molecules in primary CD4+T cells. A) CD4+T cells from a healthy human donor were exposed to the indicated
concentrations of bryostatin for 24 h before harvesting. Expression levels of cell surface CD45, CD4, CCR5, and CXCR4 were assessed by flow cytometry.
Representative flow cytometry plots are shown. B) Cells were treated as described in part A with the indicated compounds. The mean fluorescent intensity (MFI) is
provided as a percentage of that obtained for untreated cells from the same donor. ** all compounds induced significant reductions (p < 0.001) in receptor levels
(untreated vs 1000 nM). NS no compound induced significant reductions in receptor levels (untreated vs 1000 nM). *a p < 0.05 (untreated vs. 1000 nM) for all
compounds except prostratin, SUW128, and SUW132 using a 2-sided t-test. Error bars = SEM, N=3 different primary cell donors.
M.D. Marsden et al. Virology 520 (2018) 83–93
85
from integrated proviral DNA (DeChristopher et al., 2012; Kulkosky
et al., 2001). To determine the effects of the novel bryologs on HIV
spread in culture, primary CD4+T cells were costimulated via CD3
and CD28 ligation and then infected with either the CXCR4-tropic HIV
strain NL4-3 or the CCR5-tropic HIV strain NFN-SX. This latter virus is
identical to NL4-3 except for the StuI-XhoI region (encompassing most
of the virus envelope gene), which is derived from the genome of the
primary CCR5-tropic HIV isolate JR-FL (O'Brien et al., 1990). Im-
mediately following the initial 2 h infection period the cells were placed
in cultures containing a 100 nM concentration of bryostatin or in-
dividual bryologs. HIV spread under these different conditions was
measured after 3 days by quantifying HIV p24 (viral capsid) protein
levels in the culture supernatants. Each of the tested bryologs sig-
nificantly (p < 0.05) inhibited spread of both HIV variants in this
assay (Fig. 3). Interestingly, during NL4-3 infection bryostatin induced
a smaller non-statistically significant trend for reducing spread, likely
reflecting small differences in the balance between enhancement versus
inhibition of individual HIV life cycle stages between bryostatin and
bryologs mentioned above. Standard MTT cytotoxicity assays con-
ducted using CEM T cells or primary human PBMCs demonstrated that
the indicated concentrations of compounds were not cytotoxic them-
selves (Fig S1and S2). In addition, flow cytometric forward and side
scatter profiles showed no evidence of cytotoxicity under these condi-
tions.
2.3. Cytokine induction in primary peripheral blood mononuclear cells
To assess whether bryologs induce cytokine production in PBMCs,
and to compare this capacity with that of the natural compounds
prostratin and bryostatin, we treated primary human PBMCs from
healthy donors with compounds for 18 h then measured the con-
centration of several inflammation-related cytokines in the culture su-
pernatants. The amount of prostratin and bryostatin used for stimula-
tion was based on the concentration required to activate HIV from
latency in approximately 20% of J-Lat 10.6 cells. This corresponded to
concentrations of 1 µM prostratin and 10 nM bryostatin. For consistency
with bryostatin, the bryologs were also tested at 10 nM concentrations.
Additionally, 10-fold higher compound concentrations were tested in a
similar manner (Fig. 4).
Levels of TNF-alpha, IL-2 and MIP1-alpha that were induced in the
PBMC supernatant are shown (Fig. 4). TNF-alpha is particularly
important in this context because it is extremely toxic when present at
high levels in vivo. IL-2 can support proliferation of activated T cells
and might therefore exacerbate the immunological side-effects of la-
tency activation by these compounds. MIP-1 alpha is a ligand for CCR5
and is thus of interest because it can inhibit replication of R5-tropic HIV
isolates. Overall, the bryologs induced lower levels of cytokine pro-
duction than did prostratin, but the magnitude of cytokine production
varied depending on analyte compound structure, suggesting that la-
tency activation and cytokine induction are controlled differently by
different agents, and thus could each be controlled by structural var-
iations to the bryostatin scaffold.
To more easily compare the capacity of the compounds to activate
HIV from latency with their induction of cytokines in PBMCs, these data
were directly compared for two relevant cytokines. The percentage of J-
Lat 10.6 cells demonstrating activation of the latent provirus following
a 48 h stimulation with each compound was plotted against cytokine
production shown in Fig. 4 for TNF-alpha and MIP-1 alpha (Fig. 5). At
the concentrations indicated, several bryologs induced HIV from la-
tency more effectively with either no increase, or only modest increases
in cytokine production compared with bryostatin. For example, analog
SUW132 induced approximately twice as many latently-infected J-Lat
cells to express HIV (p < 0.0001) while not significantly increasing
TNF-alpha or MIP-1 alpha production (p > 0.1) in PBMCs (Fig. 5). The
majority of the bryologs also showed reduced cytokine production at
concentrations that induce similar or greater levels of latency activation
than prostratin. Hence, this decoupling of desired and undesired effects
suggests that these or related bryologs might prove advantageous over
the natural product by both improving latency activation and reducing
toxicities associated with induction of inflammatory cytokines.
2.4. Synergistic activation of HIV from latency when used with HDACi
An important direction of research in this area with potential clin-
ical consequences is the use of combinations of agents to enhance ac-
tivation at lower concentrations while also lowering off target effects.
As such, combinations of agents operating through different pathways
could prove more effective than either agent alone through synergistic
effects. For example, combinations consisting of a PKC activating agent
and a histone deacetylase inhibitor (HDACi) have shown synergistic
HIV latency activation in some cases (Albert et al., 2017; Perez et al.,
2010; Zaikos et al., 2018). To explore whether the current set of
bryologs can also synergize with well-studied HDACi's we selected sub-
optimal concentrations of each PKC modulator and one of three dif-
ferent HDACi (entinostat, vorinostat, and panobinostat) to test in-
dividually or in combination for their ability to reverse HIV latency in J-
Lat 10.6 cells. We found that bryostatin and each bryolog synergized in
combination with entinostat (Fig. 6), vorinostat (Fig S3) and panobi-
nostat (Fig S4) to produce a greater that additive induction of HIV from
latency. This suggests that such combinations are feasible with bryo-
logs, and thus could be used to further enhance efficacy and tolerability
over bryostatin (Marsden et al., 2017). By enhancing activation while
requiring lower dosing of compound, such synergistic effects could also
reduce off-target effects.
2.5. PKC binding evaluations
We have previously published PKC isoform binding affinities of
bryostatin and SUW133 (Marsden et al., 2017). For completeness in
understanding how structural variations in bryologs influence PKC
binding and downstream effects on HIV, here we have quantified
binding affinities for two additional bryologs against the full panel of
conventional and novel PKC isoforms. It is noteworthy that these and
previously reported bryologs are pan-PKC binders, although SUW128 is
a somewhat less good binder and less potent than SUW132 and
SUW133 (Table 1 and Fig. 7). This suggests that in the absence of the
C13 enoate carbonyl and in the presence of a polar C7 functionality, C9
Fig. 3. Short-term HIV spread in costimulated CD4+T cells treated with
compounds. Costimulated CD4+T cells were infected with an X4 (NL4-3) or
R5 (NFN-SX) strain of HIV and then treated with 100 nM of bryostatin 1 or the
indicated analog. Culture supernatants were harvested at d3 post-infection and
p24 concentrations were quantified by ELISA. Average p24 concentrations in
untreated cultures were 77.4 ng/mL for NL4-3 and 37.1 ng/mL for NFN-SX.
Error bars represent± 1 Standard Error (N=4 different primary cell donors).
* Indicates p < 0.05 compared with untreated control using a 2-sided t-test.
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oxygenation is necessary for strong ligand binding to PKC. This could
explain SUW128's decreased potency in HIV entry receptor down-
regulation (Fig. 2) and HIV latency reversal (Fig. 5) compared with
SUW132 and SUW133. Significantly, and of potential therapeutic
consequence, because not all PKC isoforms are implicated in activation
associated with LRA, the differing isoform affinities of SUW128 versus,
for example SUW132, suggests that variations in structure could
eventually lead to isoform selective agents.
3. Discussion
HIV latency within resting memory CD4+T cells provides a me-
chanism for long-lived persistence of the virus in ART-treated patients
(Finzi et al., 1999), thus requiring lifelong ART treatment and asso-
ciated cost, compliance and chemoexposure issues. Reduction or elim-
ination of the latent reservoir is the key to interruption of therapy or
eradication, respectively. Consequently, compounds like prostratin and
bryostatin that can induce HIV from latency via PKC activation are of
research and clinical interest in HIV eradication efforts. Indeed, the
former has been advanced preclinically and the latter has been entered
in a phase I clinical trial (Gutierrez et al., 2016). However, the previous
limited availability of these agents has hampered efforts to identify
more effective and better tolerated candidates (Barr et al., 2009; Bullen
et al., 2014). We previously addressed the supply of prostratin and
bryostatin (Wender et al., 2017, 2008), opening access to their analogs
as described previously and advanced herein. Our previous study of
earlier bryologs using a cell line HIV latency model (DeChristopher
et al., 2012) provided encouraging results on this approach to eradi-
cation. Subsequently, one particularly potent bryolog termed SUW133
was further tested ex vivo in ART-treated patient-derived cells and in
vivo in a humanized mouse model of HIV latency (Marsden et al., 2017),
the outcome of which provided further support for this approach and its
Fig. 4. Cytokine induction by compounds in
primary PBMC cultures. Primary human
PBMCs were exposed to the indicated com-
pound for 18 h and then cytokine concentra-
tions in the culture supernatant were measured
using a multiplex bead assay. Results for tumor
necrosis alpha (TNF-alpha), interleukin-2 (IL-
2), and macrophage inflammatory protein 1
alpha (MIP1-alpha) are shown. Compound
concentrations were based on a “low con-
centration” of prostratin (1 μM) or bryostatin 1
(10 nM) that induces latent HIV expression in
approximately 20% J-Lat 10.6 cells. A low
concentration of 10 nM was also used for the
bryologs. The “High concentration” corre-
sponds to 10 μM prostratin and 100 nM of
bryostatin 1 or the bryologs. Broken lines in IL-
2 charts indicate the lower level of detection
for the assay. Results from two primary cell
donors (2–3 individual stimulations for each
donor) are presented. Red * indicates
p < 0.05 compared with prostratin using a 2-
sided t-test. Green * indicates p < 0.05 com-
pared with unstimulated control using a 2-
sided t-test.
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clinical potential. The studies described here were designed to build on
these earlier findings by investigating additional and hitherto un-
explored characteristics of bryologs that are particularly relevant to
their preclinical advancement in the context of HIV eradication.
Prostratin and bryostatin can each reduce HIV entry receptor levels
(Kulkosky et al., 2001; Mehla et al., 2010; Rullas et al., 2004). This
would be advantageous in the context of activation/elimination ap-
proaches to purge HIV latency because it could lead to a reduction in
HIV spread from the recently activated latently-infected cells, thereby
aiding the antiretroviral regimen in containing the activator-induced
burst of viral expression. This could further benefit if needed from
boosting ART before LRA treatment analogous to pre-exposure pro-
phylaxis treatment. The novel bryologs also caused downregulation of
CD4, CXCR4 and CCR5 levels in CD4+T cells from HIV seronegative
donors (Fig. 2). CD45 levels were little affected in these assays. This
receptor modulation will be important to take into consideration in
future in vivo studies using these agents, where (for example) isolation
or analysis of CD4+T cells or other immune cell subsets might be
complicated by the observed transient reductions in cell surface re-
ceptor expression (Fig. 2).
Replication of both X4 and R5 variants of HIV in primary CD4+T
cells was also inhibited by treatment with the bryologs (Fig. 3) in a
short-term 3 day spreading infection assay, further supporting the
possibility that the same PKC activating agents that induce HIV from
latency could also help contain the spread of that virus to uninfected
cells. The fact that bryostatin can access sites that are poorly penetrated
by some antiretroviral drugs such as the central nervous system (Sun
and Alkon, 2006; Zhang et al., 1996) make this capacity of bryologs to
reduce HIV spread particularly interesting in the context of HIV era-
dication efforts. Further studies on the enhancement of permeation
and/or targeting of these agents, for example, through the use of gua-
nidinium-rich transporters (Stanzl et al., 2013) or lipid/vault nano-
particles (Buehler et al., 2014; Kovochich et al., 2011) could improve
the efficacy of this approach.
A key concern with HIV eradication efforts is the damaging effects
of global immune cell activation that might be caused as a by-product
of the HIV latency induction treatment. Production of pro-inflammatory
cytokines is perhaps the most direct and potentially problematic man-
ifestation of this concern. For example, TNF-alpha plays a key role in
the development of systemic inflammatory response syndrome and can
be lethal when produced at high levels (Tracey and Cerami, 1993). Both
prostratin and bryostatin can induce TNF-alpha production in primary
cells (Bosco et al., 1997; Kulkosky et al., 2001), and bryostatin
treatment has been shown to be capable of inducing some TNF-alpha
production following administration to humans (Philip et al., 1993). It
is possible that a small amount of inflammation could be beneficial in
HIV latency purging strategies, either by inducing more CD4+T cell
activation and thus higher levels of latency induction, or by enhancing
immune clearance of the cells expressing viral proteins. Agents that
induce high levels of inflammatory cytokines could potentially be used
if their toxic side-effects are managed with anti-inflammatory drugs.
However, this would add another level of complexity and uncertainty to
purging strategies. The more direct approach is to instead identify
compounds that activate HIV from latency but induce minimal levels of
cytokine production.
To gain a better understanding of the capacity for the novel bryologs
to induce cytokines, we treated PBMCs from HIV seronegative donors
with prostratin, bryostatin, or bryologs and then quantified the con-
centration of several cytokines in the culture supernatants. In these
assays, prostratin generally induced a higher level of cytokine pro-
duction than did bryostatin. The bryologs varied in their induction of
cytokines in these cultures, but in most cases induced lower levels of
cytokine production than did prostratin, thus reflecting the ability of
structural modifications in the bryostatin scaffold to effectively tune
analog activity (Fig. 4). When the cytokine induction was directly
compared with activation of HIV from latency, several bryologs showed
favorable profiles, in that they induced more latently-infected cells to
express HIV without a concomitant large increase in cytokines such as
TNF-alpha or MIP-1 alpha (Fig. 5), further indicating that variations in
structure can be used to decouple the two activities. The net effect of a
complex cytokine milieu is difficult to predict and likely depends on the
in vivo context. However, these assays do provide a broad picture of the
capacity of different compounds to perturb cytokine profiles in relevant
primary cells.
Our finding that each of these bryologs synergize with three dif-
ferent HDACi (Fig. 6, S3, and S4) is consistent with the recent ob-
servation that SUW133 can synergize with largazoles (Albert et al.,
2017) and suggests that synergy with HDACi's could be a common
feature of PKC modulators based on bryostatin scaffolds. This type of
combinatorial approach might allow lower doses of both bryologs and
HDACi to be used in vivo than would otherwise be necessary to induce
latency reactivation, thus further improving in vivo efficacy and tol-
erability compared with a single-agent approach.
The current study also provides key insights into how structural
variations in PKC modulators can affect their biological properties.
Previous computational studies have established the importance of
Fig. 5. Comparison between HIV latency activation and cytokine induction. The amount of TNF-alpha (left panel) or MIP-1 alpha (right panel) produced in primary
PBMC cultures (from Fig. 4) is plotted against the percentage of cells activated with the same concentration of compound in the J-Lat 10.6 latency assay. GFP+ cells
in the J-Lat assay represent those cells that have been activated from latency during a 24 h incubation. Relevant statistical comparisons using a 2-sided t-test are
described in the main text. Error bars represent± 1 Standard Error.
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Fig. 6. Synergistic reactivation of HIV from latency. J-Lat 10.6 cells were exposed to sub-optimal concentrations of the indicated PKC modulator alone (bryostatin 1
or SUW-designated compounds), the HDACi entinostat alone, or a combination of the two for 48 h. Lines representing the sum of values for PKC modulator alone and
entinostat alone (i.e. additive an additive response) are shown on each plot. The same entinostat alone values are presented in each plot to facilitate comparison. Data
are from 3 to 6 independent experiments. Groups were compared using an exact independent one-sided Wilcoxon rank sum test. P-values less than 0.05 are
considered significant.
Table 1
PKC binding affinities for select compounds. Values for bryostatin 1 and SUW133 are from Marsden et al. (2017). Lower Ki (nM) values indicate more effective
binding. 95% confidence intervals are in parentheses.
PKC Ki (nM)
α βI γ δ ε η θ
Bryostatin 1 0.81 (0.6–1.1) 2.2 (1.2–4.0) 2.2 (1.5–3.3) 1.1 (0.7–1.5) 3.0 (2.1–4.2) 2.2 (1.5–3.2) 1.5 (1.0–2.1)
SUW128 6.1 (4.6–8.1) 16.4 (11–25) 48 (26–89) 7.8 (5.5–11) 6.8 (4.9–9.4) 16.3 (11–25) 6.5 (3.5–12)
SUW132 2.3 (1.4–3.8) 6.3 (3.7–10.5) 4.6 (3.1–6.8) 2.9 (2.0–4.0) 2.1 (1.2–3.7) 1.8 (1.1–2.8) 2.0 (1.1–3.5)
SUW133 1.8 (1.1–2.9) 6.3 (3.5–11) 5.6 (3.1–10) 2.0 (1.3–3.0) 5.8 (2.4–14) 6.4 (3.6–10.9) 2.0 (1.1–3.6)
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binding interactions between the C13 enoate and C9 functionality in
the active ligand-PKC-membrane complex (Ryckbosch et al., 2017). The
significance of these in silico predictions are reflected in the relative PKC
binding affinities of SUW132 and SUW133 as compared to SUW128
(Table 1 and Fig. 7). While analogs SUW132 and SUW133 outperform
bryostatin-1 at inducing expression of latent proviral DNA in J-lat cells,
SUW128 is ineffective (Fig. 5) thus providing much needed information
for further analog design. This difference in function can be attributed
to their relative affinities for PKC, the upstream effector protein re-
sponsible for inducing NF-κB-mediated expression of latent proviral
DNA (Table 1 and Fig. 7). In molecular dynamics simulations of the
bryostatin-PKC-membrane ternary complex, C7 appears to be imbedded
in the hydrophobic interior of the membrane while the C9 hydroxy
group establishes a hydrogen bonding network with water molecules at
the membrane-cytosol interface (Ryckbosch et al., 2017). As such, we
would predict that analogs with a hydrophilic free hydroxy group at C7,
such as SUW128 and SUW132, could be less active or behave differ-
ently with respect to the bryostatin-PKC-membrane complex. Our data
indicate that in analogs with hydrophilic substituents at C7, C9-oxy-
genation is necessary for strong analog binding. This is consistent with
the decreased activity observed with SUW128 in nearly every assay and
the superior performance of SUW132 and SUW133. Furthermore, dif-
ferent behavior of the active enzyme complex, mediated by differential
substitution in the A- and B-rings of the bryostatin scaffold, could ex-
plain the reduced TNF-alpha response induced by the bryologs in pri-
mary PBMC cultures relative to other similarly high performing com-
pounds (Fig. 5).
Bryostatin has been in numerous oncology trials and was recently
entered into an HIV eradication trial. Prostratin is the active constituent
in a traditional medicine used in Samoa and has been advanced pre-
clinically as an LRA. In addition to tolerability, both compounds have
shown encouraging in vivo activities that could ultimately be of clinical
significance. Both natural products can now be supplied through
synthesis (Wender et al., 2017, 2008). Significantly, while the synthetic
version of these natural products might be effective clinically, these
syntheses now open the door for the design and evaluation of poten-
tially more effective, better tolerated and more accessible analogs. This
current study demonstrates that bryologs can downregulate HIV entry
receptors, inhibit HIV spread, and induce HIV from latency at con-
centrations that induce relatively low levels of proinflammatory cyto-
kine production. Furthermore, we show that each of these bryologs can
synergize with HDACi, which may represent a useful combinatorial
approach in future in vivo studies. Significantly, while the vast body of
research on LRAs over the past 20 years has been focused on several
natural products, these studies show that more accessible, effective and
better tolerated agents can be achieved through synthesis-informed
design, thus providing a potentially more effective approach to HIV
eradication and leads for other therapeutic indications.
4. Materials and methods
4.1. Cell isolation and stimulation procedures
Primary cells were cultured in “RF10 medium” consisting of RPMI
1640 medium supplemented with 10% fetal bovine serum (FBS, Omega
Scientific), 100 U/mL of penicillin, and 100 μg/mL of streptomycin
(Invitrogen). PBMCs from healthy donors were isolated using Ficoll-
Paque Plus separation (GE Healthcare). Primary CD4+T cells were
separated from PBMCs by negative immunomagnetic selection using
the CD4+T cell Isolation Kit (Miltenyi Biotec) according to the man-
ufacturer's instructions. Cells were then exposed to compound for 24 h
before staining and flow cytometric analysis of receptor levels. Prior to
infections cells were costimulated through CD3 and CD28 stimulation
to allow HIV infection. During costimulation, cells were activated using
plate-bound anti-CD3 (1 μg/mL) and soluble anti-CD28 (100 ng/mL)
antibodies in the presence of 20 U/mL of IL-2, using procedures de-
scribed previously (Marsden et al., 2012). Compound incubations with
both freshly isolated (unstimulated) and costimulated cells were per-
formed by seeding 105 cells/well in 100 μL of RF10 media containing
the appropriate concentration of compound in wells of a v-bottomed
96-well plate. Unstimulated cells were maintained throughout the
compound stimulations in RF10 medium without IL-2. Bryostatin 1
(Tocris bioscience) and Prostratin (LC Laboratories) were obtained
commercially, and bryologs were synthesized as previously described
(DeChristopher et al., 2012).
4.2. Flow cytometry
Samples of 105 cells were suspended in 50 μL of a 1:1 dilution of
phosphate buffered saline (PBS):Human AB serum (Sigma). The fol-
lowing fluorescent conjugated antibodies were then added: CCR5
(CD195)-Phycoerythrin (PE, BD Biosciences); CD4-PhycoerythrinTexas
Red (ECD, eBioscience); CXCR4 (CD183)-Allophycocyanin (APC,
eBioscience); and CD45-Phycoerythrin Cyanin 7 (PC7, BD Biosciences).
During staining, cells were incubated at 4 °C for 20min, washed with
PBS, and then resuspended in 2% paraformaldehyde. Stained samples
were stored at 4 °C, then samples were run using a Cytomics FC 500
flow cytometer (Beckman Coulter). Data was analyzed using FlowJo
(v7) software. Forward and side scatter profiles were used to exclude
dead cells.
4.3. Virus infections
HIV NL4-3 (Adachi et al., 1986) and NFN-SX (O'Brien et al., 1990)
viruses were produced by transient transfection of plasmids into 293FT
cells using Lipofectamine 2000 reagent (Invitrogen). For virus pro-
duction, a total of 6.6× 106 293FT cells per dish were seeded in 10-cm
diameter tissue culture dishes in 10mL of Opti-MEM I medium (In-
vitrogen) containing 10% FBS. The following day, the cells were
transfected with 10 μg of plasmid DNA per plate according to the Li-
pofectamine manufacturer's recommendations. The Lipofectamine/
DNA complexes were incubated with cells for 20 h, then the media was
replaced with Dulbecco's Modified Eagle Medium (Life Technologies)
containing 10% FBS. At day 2 post-transfection, the virus-containing
supernatants were harvested and filtered (0.45 µm), and then aliquots
were stored at − 80 °C. Viral p24 levels were quantified using an HIV
p24 enzyme-linked immunosorbent assay (ELISA) kit (Beckman
Coulter).
During infections, CD4+T cells were costimulated for 2–3 days
then infected in bulk by suspending 1.5×106 cells in 250 μL of RF10
media containing 20 U/mL of IL-2, 10 μg/mL of polybrene, and 75 ng of
HIV p24. Infections were allowed to proceed for 2 h on a rocking
platform at 37 °C. Cells were then washed with media, and 105 cells per
well were seeded in 100 μL of RF10 containing the relevant con-
centration of compound. The infected cultures were incubated for 3
Fig. 7. Binding affinities to conventional and novel PKC isoforms. Lower Ki
(nM) values indicate more effective binding. *= p < 0.05 using a 2-sided t-
test.
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days, and then cell-free supernatants were harvested. Supernatants
were diluted in PBS containing 2% Triton-x-100 and stored at 4 °C
before quantification of HIV p24 protein levels by ELISA.
4.4. Cytokine quantifications
PBMCs were seeded at a concentration of 105 cells per well in a v-
bottomed 96 well plate, and then 200 μL of RF10 medium containing
the relevant concentration of compound was added. After 18 h of in-
cubation, the supernatant was removed from the cells and frozen at
− 80 °C. Quantification of cytokines was performed using a custom
Milliplex Human Cytokine Magnetic Kit (Millipore) according to the
manufacturer's recommendations. Wash steps were performed using a
Bio-Plex II Wash Station (Bio-Rad), and the data was acquired using a
Bio-Plex 200 System with high-throughput fluidics (Bio-Rad). The re-
sultant data was analyzed using Bio-Plex Manager 6.1 software.
4.5. Statistical analysis
For receptor and cytokine expression level comparisons two-sided t-
tests were performed. A two-sided p-value< 0.05 between the groups
was considered significant. Where cytokine concentration values were
below the limit of detection, a value that was midway between 0 and
the limit of detection was used. For synergy analysis, data were ex-
amined for outliers and contaminants to assess deviations from para-
metric model assumptions. Groups were then compared using exact
one-sided Wilcoxon rank sum statistics, a nonparametric test. For PKC
binding analysis the 95% confidence intervals were obtained from a one
site competitive binding experiment using Graphpad Prism software
where each concentration on the curve was run in triplicate.
4.6. J-Lat cell stimulations
J-Lat cells (clone 10.6) were incubated in 100 μL volume of RF10
medium containing the indicated concentrations of compound for 48 h
before analysis. This was performed in v-bottomed 96-well tissue cul-
ture plates with a starting cell density of 25,000 cells/well. During
harvesting, cells were washed and resuspended in 2% paraformalde-
hyde. The percentage of cells expressing GFP was then quantified by
flow cytometry using a FC 500 flow cytometer (Beckman Coulter) and
FlowJo software (version 7.6).
4.7. MTT assay
Cells were seeded in v-bottomed 96-well plates in a 200 μL/well
volume of RF10 media containing the indicated concentration of
compound. After 24 h cells were subjected to a 3-(4,5-dimethylthiazol-
2-yl)−2,5-diphenyltetrazolium bromide assay (Vybrant MTT Cell
Proliferation Assay Kit, ThermoFisher Scientific) according to manu-
facturer's instructions. Cells were incubated with substrate for 4 h, lysed
and formazan solubilized, and then analyzed using a FLUOstar OPTIMA
plate reader (BMG LABTECH).
4.8. PKC Binding assay
The PKC binding assay was performed as described previously
(Marsden et al., 2017).
Acknowledgments
None.
Funding
This work was supported by grants from the National Institute of
Health (P01 AI131294, AI70010 and U19AI096113, project 3.4 to J.Z.,
CA31841 and CA31845 to P.W., AI124763 to MDM, and AI124743 to
J.Z. and P.W.), a Bill and Melinda Gates Foundation Explorations grant
(OPP1032668 to J.Z.), the James B. Pendleton Charitable Trust, the
UCLA Center for AIDS Research (AI28697), a NSF Graduate Research
Fellowship (to A.J.S.), and an American Cancer Society Postdoctoral
Fellowship (PF-15-007-01-CDD to S.H.). The funding agencies had no
role in the study design, data collection, data analysis, data inter-
pretation, or decision to submit this article for publication.
Author contributions
M.D.M., B.A.L., A.J.S., B.A.D., B.A.L., A.J.S., P.A.W., and J.A.Z.
Designed research; M.D.M., B.A.L., X.W., and A.J.S., A.J.S., C.T.H.
Performed research; M.D.M., B.A.L., X.W., S.M., C.M.R.K., D.M., B.A.D.,
B.A.L., A.J.S., P.A.W., and J.A.Z. A.J.S., C.T.H., S.H. Analyzed data;
M.D.M., A.J.S, C.T.H, S.H, B.A.L., C.M.R.K., P.A.W., and J.A.Z. Wrote
the paper; All authors contributed to the text.
Competing interests
Neurotrope Biosciences and BryoLogyx have licensed some of this
technology from Stanford University (P.A.W.), the former for the
treatment of neurological disorders such as Alzheimer's disease and the
latter for use in HIV/AIDS eradication and cancer immunotherapy.
P.A.W is a consultant to both companies and a co-founder of BryoLogyx.
J.A.Z. is on the scientific advisory board for BryoLogyx.
One sentence summary
Designed, synthetic bryostatin analogs exhibit a range of promising
activities relevant to the elimination of persistent HIV reservoirs in
addition to HIV latency reversal.
Appendix A. Supporting information
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.virol.2018.05.006.
References
Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., Martin, M.A.,
1986. Production of acquired immunodeficiency syndrome-associated retrovirus in
human and nonhuman cells transfected with an infectious molecular clone. J. Virol.
59, 284–291.
Albert, B.J., Niu, A., Ramani, R., Marshall, G.R., Wender, P.A., Williams, R.M., Ratner, L.,
Barnes, A.B., Kyei, G.B., 2017. Combinations of isoform-targeted histone deacetylase
inhibitors and bryostatin analogues display remarkable potency to activate latent HIV
without global T-cell activation. Sci. Rep. 7, 7456.
Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy, P.E., Murphy, P.M., Berger,
E.A., 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor
for macrophage-tropic HIV-1. Science 272, 1955–1958.
Archin, N.M., Liberty, A.L., Kashuba, A.D., Choudhary, S.K., Kuruc, J.D., Crooks, A.M.,
Parker, D.C., Anderson, E.M., Kearney, M.F., Strain, M.C., Richman, D.D., Hudgens,
M.G., Bosch, R.J., Coffin, J.M., Eron, J.J., Hazuda, D.J., Margolis, D.M., 2012.
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral
therapy. Nature 487, 482–485.
Barr, P.M., Lazarus, H.M., Cooper, B.W., Schluchter, M.D., Panneerselvam, A.,
Jacobberger, J.W., Hsu, J.W., Janakiraman, N., Simic, A., Dowlati, A., Remick, S.C.,
2009. Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin
lymphoma relapsing after an autologous stem cell transplant. Am. J. Hematol. 84,
484–487.
Baxter, A.E., Niessl, J., Fromentin, R., Richard, J., Porichis, F., Charlebois, R., Massanella,
M., Brassard, N., Alsahafi, N., Delgado, G.G., Routy, J.P., Walker, B.D., Finzi, A.,
Chomont, N., Kaufmann, D.E., 2016. Single-cell characterization of viral translation-
competent reservoirs in HIV-Infected Individuals. Cell Host Microbe 20, 368–380.
Beans, E.J., Fournogerakis, D., Gauntlett, C., Heumann, L.V., Kramer, R., Marsden, M.D.,
Murray, D., Chun, T.W., Zack, J.A., Wender, P.A., 2013. Highly potent, synthetically
accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc.
Natl. Acad. Sci. USA 110, 11698–11703.
Bosco, M.C., Rottschafer, S., Taylor, L.S., Ortaldo, J.R., Longo, D.L., Espinoza-Delgado, I.,
1997. The antineoplastic agent bryostatin-1 induces proinflammatory cytokine pro-
duction in human monocytes: synergy with interleukin-2 and modulation of inter-
leukin-2Rgamma chain expression. Blood 89, 3402–3411.
M.D. Marsden et al. Virology 520 (2018) 83–93
91
Buehler, D.C., Marsden, M.D., Shen, S., Toso, D.B., Wu, X., Loo, J.A., Zhou, Z.H.,
Kickhoefer, V.A., Wender, P.A., Zack, J.A., Rome, L.H., 2014. Bioengineered vaults:
self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS
Nano 8, 7723–7732.
Bullen, C.K., Laird, G.M., Durand, C.M., Siliciano, J.D., Siliciano, R.F., 2014. New ex vivo
approaches distinguish effective and ineffective single agents for reversing HIV-1
latency in vivo. Nat. Med. 20, 425–429.
Chun, T.-W., Davey, R.T., Engel, D., Lane, H.C., Fauci, A.S., 1999a. AIDS: re-emergence of
HIV after stopping therapy. Nature 401, 874–875.
Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M.,
Chadwick, K., Margolick, J., Quinn, T.C., Kuo, Y.H., Brookmeyer, R., Zeiger, M.A.,
Barditch-Crovo, P., Siliciano, R.F., 1997. Quantification of latent tissue reservoirs and
total body viral load in HIV-1 infection. Nature 387, 183–188.
Chun, T.W., Engel, D., Mizell, S.B., Hallahan, C.W., Fischette, M., Park, S., Davey Jr., R.T.,
Dybul, M., Kovacs, J.A., Metcalf, J.A., Mican, J.M., Berrey, M.M., Corey, L., Lane,
H.C., Fauci, A.S., 1999b. Effect of interleukin-2 on the pool of latently infected,
resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral
therapy. Nat. Med. 5, 651–655.
Chun, T.W., Finzi, D., Margolick, J., Chadwick, K., Schwartz, D., Siliciano, R.F., 1995. In
vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable
latency. Nat. Med. 1, 1284–1290.
Dalgleish, A.G., Beverley, P.C., Clapham, P.R., Crawford, D.H., Greaves, M.F., Weiss, R.A.,
1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS
retrovirus. Nature 312, 763–767.
Darcis, G., Kula, A., Bouchat, S., Fujinaga, K., Corazza, F., Ait-Ammar, A., Delacourt, N.,
Melard, A., Kabeya, K., Vanhulle, C., Van Driessche, B., Gatot, J.S., Cherrier, T.,
Pianowski, L.F., Gama, L., Schwartz, C., Vila, J., Burny, A., Clumeck, N., Moutschen,
M., De Wit, S., Peterlin, B.M., Rouzioux, C., Rohr, O., Van Lint, C., 2015. An in-depth
comparison of latency-reversing agent combinations in various in vitro and ex vivo
HIV-1 latency models identified bryostatin-1+JQ1 and ingenol-B+JQ1 to potently
reactivate viral gene expression. PLoS Pathog. 11, e1005063.
DeChristopher, B.A., Loy, B.A., Marsden, M.D., Schrier, A.J., Zack, J.A., Wender, P.A.,
2012. Designed, synthetically accessible bryostatin analogues potently induce acti-
vation of latent HIV reservoirs in vitro. Nat. Chem. 4, 705–710.
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P.,
Marmon, S., Sutton, R.E., Hill, C.M., Davis, C.B., Peiper, S.C., Schall, T.J., Littman,
D.R., Landau, N.R., 1996. Identification of a major co-receptor for primary isolates of
HIV-1. Nature 381, 661–666.
Dinoso, J.B., Kim, S.Y., Wiegand, A.M., Palmer, S.E., Gange, S.J., Cranmer, L., O'Shea, A.,
Callender, M., Spivak, A., Brennan, T., Kearney, M.F., Proschan, M.A., Mican, J.M.,
Rehm, C.A., Coffin, J.M., Mellors, J.W., Siliciano, R.F., Maldarelli, F., 2009.
Treatment intensification does not reduce residual HIV-1 viremia in patients on
highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 106, 9403–9408.
Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y., Nagashima, K.A., Cayanan,
C., Maddon, P.J., Koup, R.A., Moore, J.P., Paxton, W.A., 1996. HIV-1 entry into
CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667–673.
Elliott, J.H., McMahon, J.H., Chang, C.C., Lee, S.A., Hartogensis, W., Bumpus, N., Savic,
R., Roney, J., Hoh, R., Solomon, A., Piatak, M., Gorelick, R.J., Lifson, J., Bacchetti, P.,
Deeks, S.G., Lewin, S.R., 2015. Short-term administration of disulfiram for reversal of
latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2, e520–e529.
Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A., 1996. HIV-1 entry cofactor: functional
cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272,
872–877.
Finzi, D., Blankson, J., Siliciano, J.D., Margolick, J.B., Chadwick, K., Pierson, T., Smith,
K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T.C., Chaisson, R.E., Rosenberg, E.,
Walker, B., Gange, S., Gallant, J., Siliciano, R.F., 1999. Latent infection of CD4+ T
cells provides a mechanism for lifelong persistence of HIV-1, even in patients on
effective combination therapy. Nat. Med. 5, 512–517.
Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn,
T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho,
D.D., Richman, D.D., Siliciano, R.F., 1997. Identification of a reservoir for HIV-1 in
patients on highly active antiretroviral therapy. Science 278, 1295–1300.
Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Gonzalez, C., McMahon, D., Richman,
D.D., Valentine, F.T., Jonas, L., Meibohm, A., Emini, E.A., Chodakewitz, J.A., 1997.
Treatment with indinavir, zidovudine, and lamivudine in adults with human im-
munodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337,
734–739.
Gutierrez, C., Serrano-Villar, S., Madrid-Elena, N., Perez-Elias, M.J., Martin, M.E., Barbas,
C., Ruiperez, J., Munoz, E., Munoz-Fernandez, M.A., Castor, T., Moreno, S., 2016.
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral
therapy. AIDS 30, 1385–1392.
Hezareh, M., Moukil, M.A., Szanto, I., Pondarzewski, M., Mouche, S., Cherix, N., Brown,
S.J., Carpentier, J.L., Foti, M., 2004. Mechanisms of HIV receptor and co-receptor
down-regulation by prostratin: role of conventional and novel PKC isoforms. Antivir.
Chem. Chemother. 15, 207–222.
Jiang, G., Mendes, E.A., Kaiser, P., Wong, D.P., Tang, Y., Cai, I., Fenton, A., Melcher, G.P.,
Hildreth, J.E., Thompson, G.R., Wong, J.K., Dandekar, S., 2015. Synergistic
Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-
kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog. 11,
e1005066.
Kinter, A.L., Poli, G., Maury, W., Folks, T.M., Fauci, A.S., 1990. Direct and cytokine-
mediated activation of protein kinase C induces human immunodeficiency virus ex-
pression in chronically infected promonocytic cells. J. Virol. 64, 4306–4312.
Kovochich, M., Marsden, M.D., Zack, J.A., 2011. Activation of latent HIV using drug-
loaded nanoparticles. PLoS One 6, e18270.
Kulkosky, J., Culnan, D.M., Roman, J., Dornadula, G., Schnell, M., Boyd, M.R.,
Pomerantz, R.J., 2001. Prostratin: activation of latent HIV-1 expression suggests a
potential inductive adjuvant therapy for HAART. Blood 98, 3006–3015.
Kulkosky, J., Nunnari, G., Otero, M., Calarota, S., Dornadula, G., Zhang, H., Malin, A.,
Sullivan, J., Xu, Y., DeSimone, J., Babinchak, T., Stern, J., Cavert, W., Haase, A.,
Pomerantz, R.J., 2002. Intensification and stimulation therapy for human im-
munodeficiency virus type 1 reservoirs in infected persons receiving virally sup-
pressive highly active antiretroviral therapy. J. Infect. Dis. 186, 1403–1411.
Lehrman, G., Hogue, I.B., Palmer, S., Jennings, C., Spina, C.A., Wiegand, A., Landay, A.L.,
Coombs, R.W., Richman, D.D., Mellors, J.W., Coffin, J.M., Bosch, R.J., Margolis,
D.M., 2005. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
Lancet 366, 549–555.
Leth, S., Schleimann, M.H., Nissen, S.K., Hojen, J.F., Olesen, R., Graversen, M.E.,
Jorgensen, S., Kjaer, A.S., Denton, P.W., Mork, A., Sommerfelt, M.A., Krogsgaard, K.,
Ostergaard, L., Rasmussen, T.A., Tolstrup, M., Sogaard, O.S., 2016. Combined effect
of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor
vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase
1B/2A trial. Lancet HIV 3, e463–e472.
Marsden, M.D., Kovochich, M., Suree, N., Shimizu, S., Mehta, R., Cortado, R., Bristol, G.,
An, D.S., Zack, J.A., 2012. HIV latency in the humanized BLT mouse. J. Virol. 86,
339–347.
Marsden, M.D., Loy, B.A., Wu, X., Ramirez, C.M., Schrier, A.J., Murray, D., Shimizu, A.,
Ryckbosch, S.M., Near, K.E., Chun, T.W., Wender, P.A., Zack, J.A., 2017. In vivo
activation of latent HIV with a synthetic bryostatin analog effects both latent cell
"kick" and "kill" in strategy for virus eradication. PLoS Pathog. 13, e1006575.
Marsden, M.D., Zack, J.A., 2009. Eradication of HIV: current challenges and new direc-
tions. J. Antimicrob. Chemother. 63, 7–10.
Marsden, M.D., Zack, J.A., 2010. Establishment and maintenance of HIV latency: model
systems and opportunities for intervention. Future Virol. 5, 97–109.
Marsden, M.D., Zack, J.A., 2015. Experimental approaches for eliminating latent HIV.
Forum Immunopathol. Dis. Ther. 6, 91–99.
Mehla, R., Bivalkar-Mehla, S., Zhang, R., Handy, I., Albrecht, H., Giri, S., Nagarkatti, P.,
Nagarkatti, M., Chauhan, A., 2010. Bryostatin modulates latent HIV-1 infection via
PKC and AMPK signaling but inhibits acute infection in a receptor independent
manner. PLoS One 5, e11160.
Mendola, D., 2003. Aquaculture of three phyla of marine invertebrates to yield bioactive
metabolites: process developments and economics. Biomol. Eng. 20, 441–458.
Miller, I.J., Vanee, N., Fong, S.S., Lim-Fong, G.E., Kwan, J.C., 2016. Lack of overt genome
reduction in the bryostatin-producing bryozoan symbiont "Candidatus Endobugula
sertula". Appl. Environ. Microbiol. 82, 6573–6583.
O'Brien, W.A., Koyanagi, Y., Namazie, A., Zhao, J.Q., Diagne, A., Idler, K., Zack, J.A.,
Chen, I.S., 1990. HIV-1 tropism for mononuclear phagocytes can be determined by
regions of gp120 outside the CD4-binding domain. Nature 348, 69–73.
Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M.,
Ho, D.D., 1997. Decay characteristics of HIV-1-infected compartments during com-
bination therapy. Nature 387, 188–191.
Perez, M., de Vinuesa, A.G., Sanchez-Duffhues, G., Marquez, N., Bellido, M.L., Munoz-
Fernandez, M.A., Moreno, S., Castor, T.P., Calzado, M.A., Munoz, E., 2010.
Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from
latency. Curr. HIV Res. 8, 418–429.
Philip, P.A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N.S., Rockett, H., Talbot, D.C.,
Ganesan, T., Pettit, G.R., Balkwill, F., et al., 1993. Phase I study of bryostatin 1:
assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The
Cancer Research Campaign Phase I Committee. J. Natl. Cancer Inst. 85, 1812–1818.
Prins, J.M., Jurriaans, S., van Praag, R.M., Blaak, H., van Rij, R., Schellekens, P.T., ten
Berge, I.J., Yong, S.L., Fox, C.H., Roos, M.T., de Wolf, F., Goudsmit, J., Schuitemaker,
H., Lange, J.M., 1999. Immuno-activation with anti-CD3 and recombinant human IL-
2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13, 2405–2410.
Qatsha, K.A., Rudolph, C., Marme, D., Schachtele, C., May, W.S., 1993. Go 6976, a se-
lective inhibitor of protein kinase C, is a potent antagonist of human im-
munodeficiency virus 1 induction from latent/low-level-producing reservoir cells in
vitro. Proc. Natl. Acad. Sci. USA 90, 4674–4678.
Rasmussen, T.A., Tolstrup, M., Brinkmann, C.R., Olesen, R., Erikstrup, C., Solomon, A.,
Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., Lichterfeld, M., Lewin, S.R.,
Ostergaard, L., Sogaard, O.S., 2014. Panobinostat, a histone deacetylase inhibitor, for
latent-virus reactivation in HIV-infected patients on suppressive antiretroviral
therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, e13–e21.
Rullas, J., Bermejo, M., Garcia-Perez, J., Beltan, M., Gonzalez, N., Hezareh, M., Brown,
S.J., Alcami, J., 2004. Prostratin induces HIV activation and downregulates HIV re-
ceptors in peripheral blood lymphocytes. Antivir. Ther. 9, 545–554.
Ryckbosch, S.M., Wender, P.A., Pande, V.S., 2017. Molecular dynamics simulations reveal
ligand-controlled positioning of a peripheral protein complex in membranes. Nat.
Commun. 8, 6.
Schaufelberger, D.E., Koleck, M.P., Beutler, J.A., Vatakis, A.M., Alvarado, A.B., Andrews,
P., Marzo, L.V., Muschik, G.M., Roach, J., Ross, J.T., et al., 1991. The large-scale
isolation of bryostatin 1 from Bugula neritina following current good manufacturing
practices. J. Nat. Prod. 54, 1265–1270.
Schrier, A.J., 2011. Efficient Access to Bryostatin and Functional Bryostatin Analogs:
Design Synthesis and Evaluation of Potent Bryostatin Analogs and the Total Synthesis
of Bryostatin 9 Using B-Ring Annulative Macrocyclization Strategies. Stanford
University.
Stanzl, E.G., Trantow, B.M., Vargas, J.R., Wender, P.A., 2013. Fifteen years of cell-pe-
netrating, guanidinium-rich molecular transporters: basic science, research tools, and
clinical applications. Acc. Chem. Res. 46, 2944–2954.
Sun, M.K., Alkon, D.L., 2006. Bryostatin-1: pharmacology and therapeutic potential as a
CNS drug. CNS Drug Rev. 12, 1–8.
Tracey, K.J., Cerami, A., 1993. Tumor necrosis factor, other cytokines and disease. Annu.
M.D. Marsden et al. Virology 520 (2018) 83–93
92
Rev. Cell Biol. 9, 317–343.
Trindade-Silva, A.E., Lim-Fong, G.E., Sharp, K.H., Haygood, M.G., 2010. Bryostatins:
biological context and biotechnological prospects. Curr. Opin. Biotechnol. 21,
834–842.
van Praag, R.M., Prins, J.M., Roos, M.T., Schellekens, P.T., Ten Berge, I.J., Yong, S.L.,
Schuitemaker, H., Eerenberg, A.J., Jurriaans, S., de Wolf, F., Fox, C.H., Goudsmit, J.,
Miedema, F., Lange, J.M., 2001. OKT3 and IL-2 treatment for purging of the latent
HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J. Clin.
Immunol. 21, 218–226.
Wender, P.A., Cribbs, C.M., Koehler, K.F., Sharkey, N.A., Herald, C.L., Kamano, Y., Pettit,
G.R., Blumberg, P.M., 1988. Modeling of the bryostatins to the phorbol ester phar-
macophore on protein kinase C. Proc. Natl. Acad. Sci. USA 85, 7197–7201.
Wender, P.A., Donnelly, A.C., Loy, B.A., Near, K.E., Staveness, D., 2014. Rethinking the
Role of Natural Products: Function-oriented Synthesis, Bryostatin, and Bryologs,
Natural Products in Medicinal Chemistry. Wiley-VCH Verlag GmbH & Co. KGaA, pp.
473–544.
Wender, P.A., Hardman, C.T., Ho, S., Jeffreys, M.S., Maclaren, J.K., Quiroz, R.V.,
Ryckbosch, S.M., Shimizu, A.J., Sloane, J.L., Stevens, M.C., 2017. Scalable synthesis
of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358, 218–223.
Wender, P.A., Kee, J.M., Warrington, J.M., 2008. Practical synthesis of prostratin, DPP,
and their analogs, adjuvant leads against latent HIV. Science 320, 649–652.
Wender, P.A., Quiroz, R.V., Stevens, M.C., 2015. Function through synthesis-informed
design. Acc. Chem. Res. 48, 752–760.
Williams, S.A., Chen, L.F., Kwon, H., Fenard, D., Bisgrove, D., Verdin, E., Greene, W.C.,
2004. Prostratin antagonizes HIV latency by activating NF-kappaB. J. Biol. Chem.
279, 42008–42017.
Wong, J.K., Hezareh, M., Gunthard, H.F., Havlir, D.V., Ignacio, C.C., Spina, C.A.,
Richman, D.D., 1997. Recovery of replication-competent HIV despite prolonged
suppression of plasma viremia. Science 278, 1291–1295.
Zaikos, T.D., Painter, M.M., Sebastian Kettinger, N.T., Terry, V.H., Collins, K.L., 2018.
Class 1-selective histone deacetylase (HDAC) inhibitors enhance HIV latency reversal
while preserving the activity of HDAC isoforms necessary for maximal HIV gene
expression. J. Virol. 92.
Zhang, X., Zhang, R., Zhao, H., Cai, H., Gush, K.A., Kerr, R.G., Pettit, G.R., Kraft, A.S.,
1996. Preclinical pharmacology of the natural product anticancer agent bryostatin 1,
an activator of protein kinase C. Cancer Res. 56, 802–808.
M.D. Marsden et al. Virology 520 (2018) 83–93
93
